Abstract 18888: Demographic and Racial Trends of Ischemic Heart Disease Related Mortality in Patients With Cancer

Abstract

Introduction: We aim to assess the demographic and racial trends of mortality associated with Ischemic heart disease in patients diagnosed with neoplasia, between 1999 and 2020. Methods: A cross-sectional analysis of the Centers for Disease Control and Prevention Wide-Ranging Online Data for the Epidemiological Research database (CDC-WONDER) was conducted to investigate the trends in mortality associated with Ischemic heart disease (ICDcodes - I20-I25) in patients with diagnosis of neoplasm or cancer during the time of death (ICD codes C00-D48). The study calculated age-adjusted mortality rates (AAMR) per 100,000 individuals and corresponding annual percentage changes (APC), along with 95% confidence intervals, using jointpoint regression analysis. Demographic and racial trends were evaluated. Results: 359,383 Ischemic heart disease-related deaths occurred in cancer patients from 1999 to2020. Annual trends show that the AAMR decreased from 8.3 (95% CI 8.2-8.4) in 1999 to 3.3(95% CI 3.3-3.4) in 2020. The overall AAMR from 1999-2020 had an Annual PercentageChange (APC) decrease of -5 (95% CI: -5.3 to -4.7). When stratified by sex, males had a worseAAMR at 7.6 (95% CI: 0.6-0.6), and females were found to have an AAMR of 3.1 (95% CI: 0.5-0.5). When stratified by ethnicity, AAMR was highest among African Americans at 5.4 (95% CI:5.3-5.4), followed by white at 4.9 (95% CI 4.9-5.0), followed by American Indian or Alaskan Native at 2.7 (95% CI 2.6-2.9), followed by Asian or PacificIslander at 2.5 (95 % CI 2.5-2.6). Conclusions: In the United States, there has been a general decrease in IHD-associated Mortality in cancer patients from 1999 to 2020. Similar to the IHD-related mortality in the general population. Our data shows that the AAMR is worse in men, black population. In the setting of worse AAMR in specific populations, further research is needed to identify the causes and potential strategies to improve AAMR in cancer patients.